SURPASS: A Randomized, Double-Blind, Multicenter Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus (CMV) Disease in CMV Seropositive Kidney Transplant Recipients (BCV CMV vGCV)
| Status: | Terminated |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 3/9/2017 |
| Start Date: | September 2015 |
| End Date: | July 31, 2016 |
• To compare the efficacy of brincidofovir (BCV) to valganciclovir (vGCV) for the prevention
of CMV disease in kidney transplant recipients who are CMV seropositive pretransplant and
received antilymphocyte induction therapy
of CMV disease in kidney transplant recipients who are CMV seropositive pretransplant and
received antilymphocyte induction therapy
Inclusion Criteria:
- CMV seropositive (R+), who received antilymphocyte induction therapy with
antithymocyte globulin (ATG)
- First or second kidney transplant recipient
- 14 days posttransplant eGFR > 10mL/min by the C-G equation
- Able to ingest tablets
Exclusion Criteria:
- Multi organ transplant recipient
- Plasma CMV PCR > LOD by the central lab
We found this trial at
3
sites
Yale-New Haven Hospital Relying on the skill and expertise of more than 4,500 university and...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials